Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Protocol T: Little Difference In Eylea, Lucentis Efficacy At Two Years

This article was originally published in Scrip

Executive Summary

The 660-patient Protocol T clinical trial, which was designed to compare the efficacy and safety of three vascular endothelial growth factor (VEGF) inhibitors used to treat diabetic macular edema (DME), show that the efficacy gap between Regeneron Pharmaceuticals Inc.'s Eylea (aflibercept) and Genentech's Lucentis (ranibizumab) at one year narrowed with no major difference in the second year.

You may also be interested in...



Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds

Regeneron Pharmaceuticals Inc. executives emphasized the blockbuster potential of product candidates in the company's late-stage research and development pipeline on Aug. 4, while noting that the top-selling biologic Eylea (aflibercept) is facing increased reimbursement and competitive pressures.

Eisai Bets On Accelerated Approval For Biogen-Partnered Lecanemab

Following Biogen’s lead with Aduhelm, the first disease-modifying Alzheimer’s therapy approved in the US, Eisai began a rolling BLA submission for lecanemab (BAN2401) ahead of next year’s Phase III results. 

Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio

The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.

UsernamePublicRestriction

Register

SC064618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel